Nebenwirkungen · Praluent
Praluent 75 mg solution for injection in pre-filled pen Praluent 150 mg solution for injection in pre-filled pen Praluent 75 mg solution for injection in pre-filled syringe Praluent 150 mg solution for injection in pre-filled syringe Praluent 300 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 6
HOS-132685 · Präparat HOS-097282
The most common adverse reactions, at recommended doses, are local injection site reactions (6.1%), upper respiratory tract signs and symptoms (2.0%), and pruritus (1.1%). Most common adverse reactions leading to treatment discontinuation in patients treated with alirocumab were local injection site reactions. The safety profile in ODYSSEY OUTCOMES was consistent with the overall safety profile described in the Phase 3 controlled trials.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-21T12:20:00Z · SHA-256 6f3a557966433735403c271f4c209bc5a5dfed09df157b3e3075babd7406462f · Passage 0521063bdd060b5080cac7a34a4f4d9c156e11d19ab979187ac0e77f4d94e266 · Zeichen 31–472 im Abschnitt